Vycor Medical, Inc. engages in the provision of innovative surgical and therapeutic solutions to the medical community. It operates in two segments: Vycor Medical and NovaVision . The Vycor Medical segment focuses on devices for neurosurgery. The NovaVision segment offers neuro stimulation therapies and diagnostic devices for the treatment and screening of vision field loss. Vycor Medical was founded by Heather N. Vinas and Heather N. Jensen on June 17, 2005 and is headquartered in Boca Raton, FL.
Company profile
Ticker
VYCO
Exchange
Website
CEO
Peter C. Zachariou
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
203369218
VYCO stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
16 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
10-K
2022 FY
Annual report
14 Apr 23
NT 10-K
Notice of late annual filing
31 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
Latest ownership filings
SC 13D/A
FOUNTAINHEAD CAPITAL MANAGEMENT LTD
18 Oct 22
4
Change in insider ownership
18 Oct 22
4
Change in insider ownership
13 Jul 22
SC 13D/A
FOUNTAINHEAD CAPITAL MANAGEMENT LTD
13 Jul 22
SC 13D/A
FOUNTAINHEAD CAPITAL MANAGEMENT LTD
13 Apr 22
4
Change in insider ownership
13 Apr 22
4
Change in insider ownership
18 Jan 22
SC 13D/A
FOUNTAINHEAD CAPITAL MANAGEMENT LTD
18 Jan 22
SC 13D/A
FOUNTAINHEAD CAPITAL MANAGEMENT LTD
8 Oct 21
4
Change in insider ownership
8 Oct 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 69.06 k | 69.06 k | 69.06 k | 69.06 k | 69.06 k | 69.06 k |
Cash burn (monthly) | (no burn) | (no burn) | 17.16 k | 3.14 k | 4.40 k | 786.00 |
Cash used (since last report) | n/a | n/a | 114.39 k | 20.90 k | 29.34 k | 5.24 k |
Cash remaining | n/a | n/a | -45.33 k | 48.16 k | 39.71 k | 63.82 k |
Runway (months of cash) | n/a | n/a | -2.6 | 15.4 | 9.0 | 81.2 |
Institutional ownership, Q2 2022
60.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 19.80 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Fountainhead Capital Management | 19.80 mm | $0.00 |